loading
Sol Gel Technologies Ltd stock is traded at $0.812, with a volume of 37,952. It is up +3.81% in the last 24 hours and up +47.64% over the past month. Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
See More
Previous Close:
$0.7822
Open:
$0.786
24h Volume:
37,952
Relative Volume:
0.25
Market Cap:
$16.30M
Revenue:
$6.56M
Net Income/Loss:
$-14.92M
P/E Ratio:
-1.5037
EPS:
-0.54
Net Cash Flow:
$-33.87M
1W Performance:
+38.80%
1M Performance:
+47.64%
6M Performance:
+25.68%
1Y Performance:
-8.72%
1-Day Range:
Value
$0.71
$0.831
1-Week Range:
Value
$0.56
$0.831
52-Week Range:
Value
$0.334
$1.65

Sol Gel Technologies Ltd Stock (SLGL) Company Profile

Name
Name
Sol Gel Technologies Ltd
Name
Phone
-
Name
Address
-
Name
Employee
36
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
SLGL's Discussions on Twitter

Compare SLGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SLGL
Sol Gel Technologies Ltd
0.812 16.30M 6.56M -14.92M -33.87M -0.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-19-24 Downgrade Raymond James Strong Buy → Outperform
Oct-21-22 Resumed Jefferies Hold
Dec-31-19 Reiterated H.C. Wainwright Buy
Dec-31-19 Reiterated JMP Securities Mkt Outperform

Sol Gel Technologies Ltd Stock (SLGL) Latest News

pulisher
Apr 25, 2025

Basal Cell Nevus Syndrome Treatment Market 2032: EMA, PDMA, FDA - openPR.com

Apr 25, 2025
pulisher
Apr 22, 2025

Sol-Gel Technologies Ltd [SLGL] Investment Guide: What You Need to Know - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Did Sol-Gel Technologies Ltd (SLGL) perform well in the last session? - uspostnews.com

Apr 22, 2025
pulisher
Apr 17, 2025

Sol-Gel secures $16 million, extends cash runway By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Sol-Gel Technologies Secures $16 Million Deal with Mayne Pharma for U.S. Rights to EPSOLAY and TWYNEO - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Sol-Gel secures $16 million, extends cash runway - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - The Manila Times

Apr 17, 2025
pulisher
Apr 17, 2025

Sol-Gel's Strategic Pivot: $16M Product Sale Funds Promising Cancer Drug Development - Stock Titan

Apr 17, 2025
pulisher
Apr 13, 2025

XBiotech Inc. (NASDAQ:XBIT) Shares Sold by American Century Companies Inc. - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Raymond James Financial Inc. Invests $101,000 in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Raymond James Financial Inc. Purchases New Shares in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

American Century Companies Inc. Sells 20,635 Shares of AxoGen, Inc. (NASDAQ:AXGN) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Sol-Gel Technologies Ltd. (4SG.F) latest stock news and headlines - Yahoo

Apr 12, 2025
pulisher
Apr 11, 2025

Investors Don't See Light At End Of Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Tunnel And Push Stock Down 31% - simplywall.st

Apr 11, 2025
pulisher
Apr 04, 2025

Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 04, 2025
pulisher
Apr 01, 2025

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal - TipRanks

Apr 01, 2025
pulisher
Mar 30, 2025

(PDF) NaFePO4 Particles as a Cathode of Sodium Ion-Battery via Sol-Gel Method: A Review on Synthesis - ResearchGate

Mar 30, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According - openPR

Mar 12, 2025
pulisher
Mar 07, 2025

Sol Gel Technologies Ltd expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail

Mar 07, 2025
pulisher
Mar 07, 2025

Retinoic Acid Receptor Alpha Market Unlocking Growth Opportunities Through Smart Solutions - expressvartha.in

Mar 07, 2025
pulisher
Mar 05, 2025

Uremic Pruritus Clinical and Non-Clinical Studies, Key - openPR

Mar 05, 2025
pulisher
Mar 05, 2025

Sol-Gel Technologies (SLGL) to Release Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Key Driver Transforming The Rosacea Market 2025: Rising Skin Disease Prevalence Fuels Growth In The Rosacea... - WhaTech

Mar 04, 2025
pulisher
Mar 03, 2025

Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Palmoplantar Keratoderma Clinical and Non-Clinical Studies, - openPR

Mar 03, 2025
pulisher
Feb 28, 2025

Sol-Gel Coatings Market Trends, Insights, and Opportunities through 2032 - newstrail.com

Feb 28, 2025
pulisher
Feb 27, 2025

Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN

Feb 27, 2025
pulisher
Feb 25, 2025

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance

Feb 25, 2025
pulisher
Feb 18, 2025

Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Basal Cell Nevus Syndrome Treatment Market Size in the 7MM - openPR

Feb 18, 2025
pulisher
Feb 11, 2025

Biotech Stocks Facing FDA Decision In August 2021 - RTTNews

Feb 11, 2025
pulisher
Feb 07, 2025

Sol-Gel Technologies Ltd (SLGL) Shares Decline Despite Market Challenges - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Not Doing Enough For Some Investors As Its Shares Slump 51% - Simply Wall St

Feb 07, 2025
pulisher
Feb 07, 2025

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Feb 07, 2025
pulisher
Feb 07, 2025

Constellium SE’s (CSTM) Stock: A -3.86% Simple Moving Average for the Past 20 Days - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Tronox Holdings plc (TROX): A Technical Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease - Yahoo Finance

Feb 06, 2025
pulisher
Feb 04, 2025

Rosacea Clinical Trials Analysis 2025: EMA, PDMA, FDA - openPR

Feb 04, 2025
pulisher
Feb 04, 2025

Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects - Yahoo Finance

Feb 04, 2025
pulisher
Feb 03, 2025

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

Feb 03, 2025
pulisher
Jan 27, 2025

Acne Vulgaris Market Size to Reach USD 10.4 Billion by 2035, with a Growth Rate (CAGR) of 3.33% during 2025-2035 - BioSpace

Jan 27, 2025
pulisher
Jan 21, 2025

(PDF) Synthesis and Characterization of CZTS Thin Films by Sol-Gel Method without Sulfurization - ResearchGate

Jan 21, 2025
pulisher
Jan 14, 2025

Rosacea Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA - openPR

Jan 14, 2025
pulisher
Jan 13, 2025

Actinic Keratosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail

Jan 13, 2025
pulisher
Jan 13, 2025

Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail

Jan 13, 2025
pulisher
Jan 13, 2025

Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews

Jan 13, 2025
pulisher
Jan 09, 2025

DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management - Dermatology Times

Jan 09, 2025
pulisher
Jan 08, 2025

Acne Vulgaris Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News

Jan 08, 2025

Sol Gel Technologies Ltd Stock (SLGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):